Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Charmacy Pharmaceutical Co., Ltd. Class H ( (HK:2289) ).
Charmacy Pharmaceutical Co., Ltd., a Hong Kong-listed pharmaceutical company, has declared a final ordinary cash dividend of RMB 0.3 per share for the financial year ended 31 December 2025. The dividend, subject to shareholder approval on 22 May 2026, will be paid in Hong Kong dollars at an exchange rate to be announced, with the payment date set for 25 June 2026.
Key dates such as the ex-dividend date, record date, book closure period, and the applicable withholding tax details are yet to be determined and will be announced later. The dividend move signals the company’s intention to return cash to shareholders, providing income to investors while final procedural details, including Hong Kong dollar amounts and tax treatment, remain pending.
The most recent analyst rating on (HK:2289) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on Charmacy Pharmaceutical Co., Ltd. Class H stock, see the HK:2289 Stock Forecast page.
More about Charmacy Pharmaceutical Co., Ltd. Class H
Charmacy Pharmaceutical Co., Ltd. is a Hong Kong-listed pharmaceutical company operating in the healthcare sector, with its H-shares traded under stock code 02289. The company focuses on pharmaceutical products and related services, serving the broader medical and healthcare markets in Mainland China and Hong Kong.
Average Trading Volume: 10,700
Technical Sentiment Signal: Sell
Current Market Cap: HK$627.5M
For detailed information about 2289 stock, go to TipRanks’ Stock Analysis page.